Dresden: Stem Cell Therapy from Umbilical Cord Blood Saves Lives in Severe COVID & Sepsis Cases

Umbilical Cord Stem Cells Offer Hope for Severe COVID-19 and Sepsis Patients

Dresden, Germany – A novel stem cell therapy developed in Saxony, Germany, is showing promise in treating critically ill patients suffering from severe COVID-19 and sepsis. Researchers at Dresden University Hospital Carl Gustav Carus have successfully isolated stem cells from the umbilical cords of healthy newborns and are utilizing them in a therapeutic approach that appears to reduce mortality rates. While initial clinical trials took place in Canada, the foundational research and cell development originated in Dresden, offering a potential breakthrough in the treatment of these life-threatening conditions. The findings, recently published in the journal Stem Cell Reports, highlight the potential of regenerative medicine to combat severe inflammatory responses.

The core of this innovation lies in harnessing the regenerative power of mesenchymal stem cells (MSCs) found within the umbilical cord tissue. These cells possess unique anti-inflammatory and immunomodulatory properties, making them ideal candidates for tackling the “cytokine storms” characteristic of severe COVID-19 and sepsis. Cytokine storms, uncontrolled releases of inflammatory molecules, can lead to acute respiratory distress syndrome (ARDS), lung damage, and multi-organ failure – all major contributors to mortality in these conditions. The challenge, until now, has been obtaining sufficient quantities of young, viable cells for effective treatment. Researchers in Dresden have overcome this hurdle with a new method for isolating these cells from the umbilical cord, making a wider application of this therapy possible.

From Neonatal Care to Adult Treatment: A Shift in Focus

The initial impetus for this research stemmed from efforts to improve outcomes for premature and critically ill newborns. The Center for Feto-Neonatal Health at Dresden University Hospital, dedicated to the health of unborn and early-born infants, was already investigating the potential of umbilical cord stem cells to prevent chronic lung disease in this vulnerable population. As reported by TU Dresden, Professor Mario Rüdiger’s team developed and patented a novel process for isolating these mesenchymal stromal cells (MSCs) from umbilical cord tissue. This research, initially funded with 1.4 million euros from the German Federal Ministry for Economic Affairs, laid the groundwork for exploring the cells’ broader therapeutic potential.

The team recognized that the underlying pathology of severe COVID-19 and sepsis – an overactive and dysregulated immune response – shared similarities with the lung injuries seen in premature infants. This realization prompted them to investigate whether the anti-inflammatory properties of umbilical cord stem cells could be leveraged to treat adults battling these life-threatening illnesses. The approach differs from traditional stem cell therapies, which often rely on cells harvested from adult bone marrow or umbilical cord blood, sources that may contain older, less potent cells. The Dresden team’s method allows for the isolation of a larger quantity of younger, more viable cells directly from the umbilical cord tissue itself.

Clinical Trials and Early Results

The first clinical trial, conducted in Canada with approval from Health Canada on May 15, 2020, focused on patients with severe COVID-19 at risk of developing ARDS and fatal lung complications. According to the Saxony State Government, the study demonstrated a significantly lower risk of death among patients receiving the stem cell treatment. Following the abatement of the COVID-19 pandemic, researchers initiated a larger study in 2024, involving 296 patients, to assess the efficacy of the therapy in treating sepsis. Sepsis, a life-threatening condition caused by the body’s overwhelming response to an infection, is becoming increasingly difficult to treat due to the rising prevalence of antibiotic resistance.

A meta-analysis of 14 randomized, controlled studies, published in September 2024, further supports the potential of mesenchymal stem cells in treating severe COVID-19 pneumonia. The German Health Portal reports that the analysis showed MSCs can reduce mortality rates and positively influence inflammatory markers without increasing the risk of adverse events. The researchers emphasize the need for larger, randomized controlled trials to confirm these findings and establish the therapy as a standard of care.

SaxoCell: Pioneering Cellular Therapies in Saxony

The development of this innovative stem cell therapy is spearheaded by Professor Mario Rüdiger, a leading figure in regenerative medicine. He is one of the directors of SaxoCell, a research center funded by the German federal government and a collaborative effort between the universities of Leipzig and Dresden. SaxoCell is dedicated to developing and translating cellular therapies “Made in Saxony” into clinical practice. The center aims to establish Saxony as a hub for innovation in regenerative medicine, focusing on the development of cell-based therapies for a range of diseases.

“If the data are confirmed, a therapy originally developed for infants could revolutionize the treatment of adults,” explains Professor Rüdiger. Uwe Platzbecker, Medical Director of the University Hospital Dresden, echoed this sentiment, stating that the preliminary results demonstrate the potential of innovative cell-based therapies to address severe inflammatory conditions. The University Hospital Dresden is committed to supporting the translation of this research into routine clinical care.

Key Takeaways

• Umbilical cord stem cells show promise in reducing mortality for patients with severe COVID-19 and sepsis.
• A novel isolation technique developed in Dresden allows for the efficient harvesting of young, viable stem cells from umbilical cord tissue.
• Clinical trials in Canada have demonstrated positive results, with ongoing research focused on sepsis treatment.
• SaxoCell, a collaborative research center, is driving the development and translation of cellular therapies in Saxony, Germany.

The ongoing study on sepsis, involving 296 patients, is crucial for validating the effectiveness of this therapy and paving the way for its wider adoption. Researchers will be closely monitoring patient outcomes and analyzing data to determine the optimal dosage and treatment protocols. The results of this study are expected to be available in the coming months, potentially marking a significant advancement in the fight against sepsis, a condition that claims hundreds of thousands of lives globally each year. The future of this research also includes exploring the potential of these stem cells in treating other inflammatory diseases, offering hope for patients with a wide range of conditions.

As research progresses, the potential for personalized medicine using umbilical cord stem cells becomes increasingly apparent. The ability to tailor treatments based on individual patient characteristics could further enhance the efficacy and safety of these therapies. The work being done in Dresden and Leipzig represents a significant step forward in the field of regenerative medicine, offering a new avenue for treating some of the most challenging and life-threatening illnesses facing humanity.

The next key milestone will be the publication of the full results from the ongoing sepsis trial, anticipated in late 2026. We encourage readers to share this article and engage in the conversation about the potential of stem cell therapies to transform healthcare.